» Articles » PMID: 26619011

Identifying Recurrent Mutations in Cancer Reveals Widespread Lineage Diversity and Mutational Specificity

Overview
Journal Nat Biotechnol
Specialty Biotechnology
Date 2015 Dec 1
PMID 26619011
Citations 439
Authors
Affiliations
Soon will be listed here.
Abstract

Mutational hotspots indicate selective pressure across a population of tumor samples, but their prevalence within and across cancer types is incompletely characterized. An approach to detect significantly mutated residues, rather than methods that identify recurrently mutated genes, may uncover new biologically and therapeutically relevant driver mutations. Here, we developed a statistical algorithm to identify recurrently mutated residues in tumor samples. We applied the algorithm to 11,119 human tumors, spanning 41 cancer types, and identified 470 somatic substitution hotspots in 275 genes. We find that half of all human tumors possess one or more mutational hotspots with widespread lineage-, position- and mutant allele-specific differences, many of which are likely functional. In total, 243 hotspots were novel and appeared to affect a broad spectrum of molecular function, including hotspots at paralogous residues of Ras-related small GTPases RAC1 and RRAS2. Redefining hotspots at mutant amino acid resolution will help elucidate the allele-specific differences in their function and could have important therapeutic implications.

Citing Articles

A Pilot Study of and Gene Variants in Primary Hyperparathyroidism.

Chorti A, Achilla C, Siasiaridis A, Aristeidis I, Cheva A, Theodosios P Balkan J Med Genet. 2025; 27(2):33-39.

PMID: 40070855 PMC: 11892936. DOI: 10.2478/bjmg-2024-0011.


The Development of ATM Inhibitors in Cancer Therapy.

Ampolini E, Jimenez-Sainz J, Long D Target Oncol. 2025; .

PMID: 40024979 DOI: 10.1007/s11523-025-01136-6.


De novo familial adenomatous polyposis with germline double heterozygosity of APC/BRCA2: a case report and literature review.

Zhang T, Cai J, Li C, Xu Y, Xu Y Hered Cancer Clin Pract. 2025; 23(1):6.

PMID: 39985003 PMC: 11843810. DOI: 10.1186/s13053-025-00306-x.


Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease.

Kravchuk D, Lebedeva A, Kuznetsova O, Kavun A, Taraskina A, Belova E Front Immunol. 2025; 16:1492296.

PMID: 39975556 PMC: 11836019. DOI: 10.3389/fimmu.2025.1492296.


A multiscale functional map of somatic mutations in cancer integrating protein structure and network topology.

Zhang Y, Leung A, Kang J, Sun Y, Wu G, Li L Nat Commun. 2025; 16(1):975.

PMID: 39856048 PMC: 11760531. DOI: 10.1038/s41467-024-54176-3.


References
1.
Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

2.
Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

3.
Karolchik D, Barber G, Casper J, Clawson H, Cline M, Diekhans M . The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 2013; 42(Database issue):D764-70. PMC: 3964947. DOI: 10.1093/nar/gkt1168. View

4.
Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N . Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014; 4(9):1014-21. PMC: 4155059. DOI: 10.1158/2159-8290.CD-14-0380. View

5.
Rosario M, PATERSON H, Marshall C . Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21. Mol Cell Biol. 2001; 21(11):3750-62. PMC: 87018. DOI: 10.1128/MCB.21.11.3750-3762.2001. View